|Dr. Troy Edward Wilson||Co-Founder & Chairman||132k||N/A||1969|
|Ms. Sarah Boyce||Pres, CEO & Director||823.09k||N/A||1972|
|Mr. Michael F. MacLean||Chief Financial Officer||501.34k||N/A||1966|
|Prof. Mark E. Davis||Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s||N/A||N/A||N/A|
|Dr. Frank McCormick Ph.D.||Scientific Founder & Member of Scientific Advisory Board||N/A||N/A||1950|
|Mr. Joseph Baroldi||Chief Operating Officer||N/A||N/A||1978|
|Dr. W. Michael Flanagan Ph.D.||Chief Technical Officer||N/A||N/A||1962|
|Dr. Arthur A. Levin||Chief Scientific Officer||N/A||N/A||1954|
|Dr. John W. Wallen III||VP of Intellectual Property, Gen. Counsel & Sec.||N/A||N/A||1958|
|Ms. Teresa McCarthy||Chief HR Officer||N/A||N/A||N/A|
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Avidity Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 9.